Merz Pharmaceuticals, LLC takes another step in delivering value to our customers by reducing the price of XEOMIN® (incobotulinumtoxinA) by almost 20 percent.
To ensure access to Xeomin therapy for the greatest number of patients effective October 6, 2011, XEOMIN’s price has been reduced by nearly 20 percent. This change was initiated by Merz as part of its ongoing efforts to ensure broad access to XEOMIN for patients who have come to rely on this highly refined molecule, which is free from accessory proteins.
XEOMIN has been available in the U.S. for one year and, along with Merz, has established a very positive presence in the cervical dystonia and blepharospasm communities. Merz is committed to all stakeholders and will maintain this price advantage for XEOMIN while continuing to provide best-in-class patient and physician support and services.